Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?

Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use in reducing new heterotopic ossification lesions and flare ups. The 84 week OPTIMA readout suggests a sustained effect in limiting new rogue bone formation and flare ups while maintaining a generally consistent safety profile. This could reinforce...